MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31, MBOT had -$56K decrease in cash & cash equivalents over the period. -$5,161K in free cash flow.

Cash Flow Overview

Change in Cash
-$56K
Free Cash flow
-$5,161K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from sales of a marketa...
    • Other payables and accrued liabi...
    • Share-based compensation
    • Others
Negative Cash Flow Breakdown
    • Inventory
    • Increase in restricted deposit
    • Purchases of marketable securiti...
    • Others

Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Net loss
-3,671 -3,464 -3,577 -6,101
Depreciation of property and equipment
12 10 10 27
Interest income and unrealized gains from marketable securities
-60 -163 119
Share-based compensation
222 236 328 493
Accounts receivable
105 ---
Inventory
1,673 584 --
Prepaid expenses and other assets
-7 336 -161
Insurance recovery related to legal settlement and legal expenses received in cash
---0
Accounts payable and accrued liabilities
-495 --
Legal settlement paid in cash
---0
Change in long-term deposit
-737 --
Other payables and accrued liabilities
395 --103 92
Proceeds from maturities of marketable securities
---0
Net cash flows used in operating activities
-5,053 -3,758 -3,841 -5,447
Purchases of property and equipment
108 25 13 22
Purchase of marketable securities
-3,008 48,000 31,918
Purchases of marketable securities
441 ---
Proceeds from sales of a marketable securities
6,500 1,500 3,301 5,801
Increase in long-term deposit
148 ---
Increase in restricted deposit
806 ---
Net cash flows provided by (used in) investing activities
4,997 -1,533 -44,712 -26,139
Issuance of common stock and warrants, net
--83,733 -
Issuance of common stock and warrants, net of issuance costs
-53,681 -32,558
Exercise of options
-0 1 -
Net cash flows provided by financing activities
-2,506 51,176 32,558
(decrease) increase in cash, cash equivalents and restricted cash
-56 -2,785 2,623 972
Cash, cash equivalents and restricted cash at beginning of period
3,973 6,758 3,163 -
Cash, cash equivalents and restricted cash at end of period
3,917 3,973 6,758 -
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from sales of amarketable securities$6,500K Net cash flowsprovided by (used in)...$4,997K Canceled cashflow$1,503K (decrease) increase incash, cash...-$56K Canceled cashflow$4,997K Other payables andaccrued liabilities$395K Share-based compensation$222K Interest income andunrealized gains from...-$60K Depreciation of property andequipment$12K Increase in restricteddeposit$806K Purchases of marketablesecurities$441K Increase in long-termdeposit$148K Purchases of property andequipment$108K Net cash flows usedin operating...-$5,053K Canceled cashflow$689K Net loss-$3,671K Inventory$1,673K something is missing-$293K Accounts receivable$105K

Microbot Medical Inc. (MBOT)

Microbot Medical Inc. (MBOT)